130 results on '"Pesapane F"'
Search Results
2. Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis
- Author
-
Floridi, C., Pesapane, F., Angileri, S. A., De Palma, D., Fontana, F., Caspani, F., Barile, A., Del Sole, A., Masciocchi, C., Lucignani, G., and Carrafiello, G.
- Published
- 2017
- Full Text
- View/download PDF
3. New concepts in embolotherapy of HCC
- Author
-
Pesapane, F., Nezami, N., Patella, F., and Geschwind, J. F.
- Published
- 2017
- Full Text
- View/download PDF
4. ‘Dumbo’ ear
- Author
-
Vaira, F., Nazzaro, G., Pesapane, F., and Veraldi, S.
- Published
- 2014
- Full Text
- View/download PDF
5. Tricholemmoma, sebaceoma, syringocystadenoma papilliferum, basal cell carcinoma, trichilemmal cyst arising within a nevus sebaceous
- Author
-
GIANLUCA NAZZARO, Vaira, F., Pesapane, F., Coggi, A., and Gianotti, R.
6. Diagnostic performance of image-guided vacuum-assisted breast biopsy after neoadjuvant therapy for breast cancer: prospective pilot study
- Author
-
Elisabetta M C Rossi, Alessandra Invento, Filippo Pesapane, Eleonora Pagan, Vincenzo Bagnardi, Nicola Fusco, Konstantinos Venetis, Valeria Dominelli, Chiara Trentin, Enrico Cassano, Laura Gilardi, Manuelita Mazza, Matteo Lazzeroni, Francesca De Lorenzi, Pietro Caldarella, Alessandra De Scalzi, Antonia Girardi, Claudia Sangalli, Luca Alberti, Virgilio Sacchini, Viviana Galimberti, Paolo Veronesi, Rossi, E, Invento, A, Pesapane, F, Pagan, E, Bagnardi, V, Fusco, N, Venetis, K, Dominelli, V, Trentin, C, Cassano, E, Gilardi, L, Mazza, M, Lazzeroni, M, De Lorenzi, F, Caldarella, P, De Scalzi, A, Girardi, A, Sangalli, C, Alberti, L, Sacchini, V, Galimberti, V, and Veronesi, P
- Subjects
Breast biposy ,Surgery - Abstract
Background Image-guided vacuum-assisted breast biopsy (VABB) of the tumour bed, performed after neoadjuvant therapy, is increasingly being used to assess residual cancer and to potentially identify to identify pathological complete response (pCR). In this study, the accuracy of preoperative VABB specimens was assessed and compared with surgical specimens in patients with triple-negative or human epidermal growth factor receptor 2 (HER2)-positive invasive ductal breast cancer after neoadjuvant therapy. As a secondary endpoint, the performance of contrast-enhanced MRI of the breast and PET–CT for response prediction was assessed. Methods This single-institution prospective pilot study enrolled patients from April 2018 to April 2021 with a complete response on imaging (iCR) who subsequently underwent VABB before surgery. Those with a pCR at VABB were included in the primary analysis of the accuracy of VABB. The performance of imaging (MRI and PET–CT) was analysed for prediction of a pCR considering both patients with an iCR and those with residual disease at postneoadjuvant therapy imaging. Results Twenty patients were included in the primary analysis. The median age was 44 (range 35–51) years. At surgery, 18 of 20 patients showed a complete response (accuracy 90 (95 per cent exact c.i. 68 to 99) per cent). Only two patients showed residual ductal intraepithelial neoplasia of grade 2 and 3 respectively. In the secondary analysis, accuracy was similar for MRI and PET–CT (77 versus 78 per cent; P = 0.76). Conclusion VABB in patients with an iCR might be a promising method to select patients for de-escalation of surgical treatment in triple-negative or HER2-positive breast cancer. The present results support such an approach and should inform the design of future trials on de-escalation of surgery.
- Published
- 2022
7. Breast Imaging Reporting and Data System and Contrast Enhancement Mammography: Lesion Conspicuity Likelihood of Malignancy and Relationship With Breast Tumor Receptor Status
- Author
-
Luca Nicosia, Anna Carla Bozzini, Simone Palma, Filippo Pesapane, Lorenza Meneghetti, Maria Pizzamiglio, Francesca Abbate, Antuono Latronico, Vincenzo Bagnardi, Samuele Frassoni, Claudia Sangalli, Enrico Cassano, Nicosia, L, Bozzini, A, Palma, S, Pesapane, F, Meneghetti, L, Pizzamiglio, M, Abbate, F, Latronico, A, Bagnardi, V, Frassoni, S, Sangalli, C, and Cassano, E
- Subjects
Contrast Enhanced Mammography ,Breast neoplasm ,Multimodal imaging ,Radiology, Nuclear Medicine and imaging ,Mammography - Abstract
Rationale and Objectives: The new version of the Contrast Enhanced Mammography (CEM) Breast imaging Reporting and Data System (BIRADs) encourages investigations of a new enhancement descriptor: “Lesion Conspicuity” (LC). The study aims to assess the diagnostic performance and the relationship with the receptor profile of this new enhancement descriptor. Materials and Methods: Three hundred twenty-five patients with 381 breast lesions who underwent CEM before histological assessmentwere selected. Four radiologists, blinded to each other, categorized LC into the following levels: absent, low, moderate, and high. Considering moderate and high evaluations as predictive of malignancy, the diagnostic performance of CEM was calculated using histological results of the biopsy as the gold standard. The association between LC values and the receptor profile of the neoplasms was also evaluated. Results: The median age at the CEM examination was 50 years (IQR: 45-59). Considering the value of LC of the most experienced radiologist with the interpretation of Low Energy images (LE), we obtained a sensitivity (SE) of 91.9% (95% CI: 88.6%-95.2%) and a specificity (SP) of 67.2% (95% CI: 58.9%-75.5%). An association between “high” lesion conspicuity with ER/PgR not expressed (p = 0.025), with Ki-67>20% (p = 0.033), and with Grading G3 (p = 0.020) was observed. Conclusion: The new feature of enhancement, “Lesion Conspicuity”, demonstrated satisfactory performance in predicting the malignancy of lesions and significant correlation with the receptor profile of malignant breast neoplasms.
- Published
- 2023
8. The Use of Artificial Intelligence (AI) in the Radiology Field: What Is the State of Doctor–Patient Communication in Cancer Diagnosis?
- Author
-
Alexandra Derevianko, Silvia Francesca Maria Pizzoli, Filippo Pesapane, Anna Rotili, Dario Monzani, Roberto Grasso, Enrico Cassano, Gabriella Pravettoni, Derevianko A., Pizzoli S.F.M., Pesapane F., Rotili A., Monzani D., Grasso R., Cassano E., and Pravettoni G.
- Subjects
Cancer Research ,Oncology ,communication ,decision-making ,artificial intelligence ,patient empowerment - Abstract
Simple Summary Artificial Intelligence (AI) has been increasingly used in radiology to improve diagnostic procedures over the past decades. The application of AI at the time of cancer diagnosis also creates challenges in the way doctors should communicate the use of AI to patients. The present systematic review deals with the patient's psycho-cognitive perspective on AI and the interpersonal skills between patients and physicians when AI is implemented in cancer diagnosis communication. Evidence from the retrieved studies pointed out that the use of AI in radiology is negatively associated with patient trust in AI and patient-centered communication in cancer disease. Background: In the past decade, interest in applying Artificial Intelligence (AI) in radiology to improve diagnostic procedures increased. AI has potential benefits spanning all steps of the imaging chain, from the prescription of diagnostic tests to the communication of test reports. The use of AI in the field of radiology also poses challenges in doctor-patient communication at the time of the diagnosis. This systematic review focuses on the patient role and the interpersonal skills between patients and physicians when AI is implemented in cancer diagnosis communication. Methods: A systematic search was conducted on PubMed, Embase, Medline, Scopus, and PsycNet from 1990 to 2021. The search terms were: ("artificial intelligence" or "intelligence machine") and "communication" "radiology" and "oncology diagnosis". The PRISMA guidelines were followed. Results: 517 records were identified, and 5 papers met the inclusion criteria and were analyzed. Most of the articles emphasized the success of the technological support of AI in radiology at the expense of patient trust in AI and patient-centered communication in cancer disease. Practical implications and future guidelines were discussed according to the results. Conclusions: AI has proven to be beneficial in helping clinicians with diagnosis. Future research may improve patients' trust through adequate information about the advantageous use of AI and an increase in medical compliance with adequate training on doctor-patient diagnosis communication.
- Published
- 2023
9. Contrast-Enhanced Spectral Mammography in the Evaluation of Breast Microcalcifications: Controversies and Diagnostic Management
- Author
-
Luca Nicosia, Anna Carla Bozzini, Giulia Signorelli, Simone Palma, Filippo Pesapane, Samuele Frassoni, Vincenzo Bagnardi, Maria Pizzamiglio, Mariagiorgia Farina, Chiara Trentin, Silvia Penco, Lorenza Meneghetti, Claudia Sangalli, Enrico Cassano, Nicosia, L, Bozzini, A, Signorelli, G, Palma, S, Pesapane, F, Frassoni, S, Bagnardi, V, Pizzamiglio, M, Farina, M, Trentin, C, Penco, S, Meneghetti, L, Sangalli, C, and Cassano, E
- Subjects
microcalcification ,breast cancer ,Health Information Management ,Leadership and Management ,CESM ,Health Policy ,Health Informatics ,microcalcifications ,breast biopsy - Abstract
The aim of this study was to evaluate the diagnostic performance of contrast-enhanced spectral mammography (CESM) in predicting breast lesion malignancy due to microcalcifications compared to lesions that present with other radiological findings. Three hundred and twenty-one patients with 377 breast lesions that underwent CESM and histological assessment were included. All the lesions were scored using a 4-point qualitative scale according to the degree of contrast enhancement at the CESM examination. The histological results were considered the gold standard. In the first analysis, enhancement degree scores of 2 and 3 were considered predictive of malignity. The sensitivity (SE) and positive predictive value (PPV) were significative lower for patients with lesions with microcalcifications without other radiological findings (SE = 53.3% vs. 82.2%, p-value < 0.001 and PPV = 84.2% vs. 95.2%, p-value = 0.049, respectively). On the contrary, the specificity (SP) and negative predictive value (NPV) were significative higher among lesions with microcalcifications without other radiological findings (SP = 95.8% vs. 84.2%, p-value = 0.026 and NPV = 82.9% vs. 55.2%, p-value < 0.001, respectively). In a second analysis, degree scores of 1, 2, and 3 were considered predictive of malignity. The SE (80.0% vs. 96.8%, p-value < 0.001) and PPV (70.6% vs. 88.3%, p-value: 0.005) were significantly lower among lesions with microcalcifications without other radiological findings, while the SP (85.9% vs. 50.9%, p-value < 0.001) was higher. The enhancement of microcalcifications has low sensitivity in predicting malignancy. However, in certain controversial cases, the absence of CESM enhancement due to its high negative predictive value can help to reduce the number of biopsies for benign lesions
- Published
- 2023
10. Breast Digital Tomosynthesis versus Contrast-Enhanced Mammography: Comparison of Diagnostic Application and Radiation Dose in a Screening Setting
- Author
-
Luca Nicosia, Anna Carla Bozzini, Filippo Pesapane, Anna Rotili, Irene Marinucci, Giulia Signorelli, Samuele Frassoni, Vincenzo Bagnardi, Daniela Origgi, Paolo De Marco, Ida Abiuso, Claudia Sangalli, Nicola Balestreri, Giovanni Corso, Enrico Cassano, Nicosia, L, Bozzini, A, Pesapane, F, Rotili, A, Marinucci, I, Signorelli, G, Frassoni, S, Bagnardi, V, Origgi, D, De Marco, P, Abiuso, I, Sangalli, C, Balestreri, N, Corso, G, and Cassano, E
- Subjects
Cancer Research ,Oncology ,Digital Breast Tomosynthesi ,Contrast-Enhanced Mammography ,Digital Breast Tomosynthesis ,breast cancer screening ,Average Glandular Dose - Abstract
This study aims to evaluate the Average Glandular Dose (AGD) and diagnostic performance of CEM versus Digital Mammography (DM) as well as versus DM plus one-view Digital Breast Tomosynthesis (DBT), which were performed in the same patients at short intervals of time. A preventive screening examination in high-risk asymptomatic patients between 2020 and 2022 was performed with two-view Digital Mammography (DM) projections (Cranio Caudal and Medio Lateral) plus one Digital Breast Tomosynthesis (DBT) projection (mediolateral oblique, MLO) in a single session examination. For all patients in whom we found a suspicious lesion by using DM + DBT, we performed (within two weeks) a CEM examination. AGD and compression force were compared between the diagnostic methods. All lesions identified by DM + DBT were biopsied; then, we assessed whether lesions found by DBT were also highlighted by DM alone and/or by CEM. We enrolled 49 patients with 49 lesions in the study. The median AGD was lower for DM alone than for CEM (3.41 mGy vs. 4.24 mGy, p = 0.015). The AGD for CEM was significantly lower than for the DM plus one single projection DBT protocol (4.24 mGy vs. 5.55 mGy, p < 0.001). We did not find a statistically significant difference in the median compression force between the CEM and DM + DBT. DM + DBT allows the identification of one more invasive neoplasm one in situ lesion and two high-risk lesions, compared to DM alone. The CEM, compared to DM + DBT, failed to identify only one of the high-risk lesions. According to these results, CEM could be used in the screening of asymptomatic high-risk patients.
- Published
- 2023
11. Contrast-Enhanced Spectral Mammography and tumor size assessment: a valuable tool for appropriate surgical management of breast lesions
- Author
-
Luca Nicosia, Anna Carla Bozzini, Simone Palma, Marta Montesano, Giulia Signorelli, Filippo Pesapane, Antuono Latronico, Vincenzo Bagnardi, Samuele Frassoni, Claudia Sangalli, Mariagiorgia Farina, Enrico Cassano, Nicosia, L, Bozzini, A, Palma, S, Montesano, M, Signorelli, G, Pesapane, F, Latronico, A, Bagnardi, V, Frassoni, S, Sangalli, C, Farina, M, and Cassano, E
- Subjects
Size estimation ,Contrast Media ,Breast Neoplasms ,General Medicine ,Magnetic Resonance Imaging ,Sensitivity and Specificity ,CESM ,Neoplasms ,Humans ,Female ,Radiology, Nuclear Medicine and imaging ,Surgery ,Breast ,Mammography ,MRI - Abstract
Purpose: To compare the accuracy of Contrast-Enhanced Spectral Mammography (CESM), MG, US, and breast MRI in estimating the size of breast lesions requiring surgery. The postoperative histology size of the lesion was used as the gold standard. Material and methods: Two hundred thirty-three non-benign lesions in 189 patients were included in the analyses. All the selected patients underwent CESM and at least one other conventional diagnostic exam (US, MG, or MRI). Subsequently, all the patients underwent surgery preceded by cytological/histological examination. The largest diameter of the lesion at imaging was measured by a radiologist with more than 10years’ experience and then compared with the size of the lesion in the histological sample at the surgery (gold standard). Results: Among the 233 breast lesions, 196 were evaluated with US, 206 with MG and 160 with MRI. We found no statistically significant differences between size measurements using CESM and MRI compared with the measurements at the surgery (p value 0.63 and 0.51), whereas a significant difference was found for MG and US (p < 0.001). Conclusion: CESM is a reliable method for estimating the size of breast lesions: its performance seems superior to US and MG and comparable to MRI.
- Published
- 2022
12. Ductal carcinoma in situ of the male breast: clinical radiological features and management in a cancer referral center
- Author
-
Luca Nicosia, Germana Lissidini, Manuela Sargenti, Anna Carla Bozzini, Gabriel Farante, José Vila, Chiara Oriecuia, Eleonora Pagan, Vincenzo Bagnardi, Matteo Lazzeroni, Filippo Pesapane, Claudia Sangalli, Viviana Galimberti, Enrico Cassano, Paolo Veronesi, Nicosia, L, Lissidini, G, Sargenti, M, Bozzini, A, Farante, G, Vila, J, Oriecuia, C, Pagan, E, Bagnardi, V, Lazzeroni, M, Pesapane, F, Sangalli, C, Galimberti, V, Cassano, E, and Veronesi, P
- Subjects
Adult ,Aged, 80 and over ,Male ,Cancer Research ,Disease-free survival ,Carcinoma, Ductal, Breast ,Breast Neoplasms ,Middle Aged ,Male DCIS ,Mastectomy, Segmental ,Breast Neoplasms, Male ,Young Adult ,Carcinoma, Intraductal, Noninfiltrating ,Ki-67 Antigen ,Oncology ,Humans ,Surgery ,Breast ,Neoplasm Recurrence, Local ,Referral and Consultation ,Mastectomy ,Aged ,Retrospective Studies - Abstract
Purpose To present an overview of the management of male patients with Ductal Carcinoma In Situ of the breast (male DCIS). Methods We retrospectively studied all male patients with a diagnosis of pure DCIS from January 1999 to December 2018: 20 patients were identified in our cancer referral center. We collected data regarding clinical presentation, age of onset, radiological features, receptor status of the neoplasm, histological type, and the follow-up of those patients. Results The median age was 62 years (range 21–80). All patients underwent surgery, in 15/20 (75%) cases a mastectomy was carried out. Two patients (10%) underwent endocrine treatment and 1/20 (5%) underwent radiotherapy. The receptor status for 15/20 patients was documented: 13/15 patients were ER+/Pr+. In 3 cases the Ki 67% was positive (i.e., > 20%). All cases were negative for Her2. The median follow-up time was 9.0 years (IQR 4.0–13.7). Only one patient had an ipsilateral recurrence with the finding of an infiltrating carcinoma in the same breast after 14 years. The 5-year disease-free survival was 92.9%. Conclusion Pure DCIS in men is an extremely rare disease: proper diagnosis and management allow an excellent prognosis.
- Published
- 2022
13. Quantification of heterogeneity to classify benign parotid tumors: a feasibility study on most frequent histotypes
- Author
-
Gabriele Maria Nicolino, Mario Petrillo, Giuseppe Franceschelli, Laura Tofanelli, Filippo Pesapane, Giorgio Buccimazza, Massimo Fusco, Federico Biglioli, Vissagan Gopalakrishnan, Roberta Fusco, Francesca Patella, Mario Sansone, Maurizio Cariati, Patella, F., Sansone, M., Franceschelli, G., Tofanelli, L., Petrillo, M., Fusco, M., Nicolino, G. M., Buccimazza, G., Fusco, R., Gopalakrishnan, V., Pesapane, F., Biglioli, F., and Cariati, M.
- Subjects
Male ,pleomorphic adenoma ,Cancer Research ,Multivariate analysis ,030218 nuclear medicine & medical imaging ,0302 clinical medicine ,parotid tumor ,volume of interest ,Image Processing, Computer-Assisted ,Medicine ,Intravoxel incoherent motion ,intravoxel incoherent motion ,Aged, 80 and over ,medicine.diagnostic_test ,Histocytochemistry ,Area under the curve ,General Medicine ,Middle Aged ,Magnetic Resonance Imaging ,Parotid Neoplasms ,Oncology ,030220 oncology & carcinogenesis ,Female ,Warthin tumor ,histogram ,Algorithms ,Adult ,Adolescent ,DCE-MRI ,magnetic resonance ,Young Adult ,03 medical and health sciences ,DW-MRI ,Histogram ,Humans ,Aged ,Neoplasm Staging ,Retrospective Studies ,Receiver operating characteristic ,business.industry ,Warthin Tumor ,Magnetic resonance imaging ,Models, Theoretical ,Biological Variation, Population ,ROC Curve ,Skewness ,Feasibility Studies ,Neoplasm Grading ,business ,Nuclear medicine - Abstract
Aim: To differentiate Warthin tumors (WTs) and pleomorphic adenomas (PAs) measuring heterogeneity of intravoxel incoherent motion (IVIM) and dynamic-contrast enhanced-magnetic resonance imaging biomarkers. Methods: Volumes of interest were traced on 18 WT and 18 PA in 25 patients. For each IVIM and dynamic-contrast enhanced biomarker, histogram parameters were calculated and then compared using the Wilcoxon-signed-rank test. Receiver operating characteristic curves and multivariate analysis were employed to identify the parameters and their pairs with the best accuracy. Results: Most of the biomarkers exhibited significant difference (p < 0.05) between PA and WT for histogram parameters. Time to peak median and skewness, and D* median and entropy showed the highest area under the curve. No meaningful improvement of accuracy was obtained using two features. Conclusion: IVIM and dynamic-contrast enhanced histogram descriptors may help in the classification of WT and PA.
- Published
- 2020
14. A Score to Predict the Malignancy of a Breast Lesion Based on Different Contrast Enhancement Patterns in Contrast-Enhanced Spectral Mammography
- Author
-
Luca Nicosia, Anna Carla Bozzini, Simone Palma, Marta Montesano, Filippo Pesapane, Federica Ferrari, Valeria Dominelli, Anna Rotili, Lorenza Meneghetti, Samuele Frassoni, Vincenzo Bagnardi, Claudia Sangalli, Enrico Cassano, Nicosia, L, Bozzini, A, Palma, S, Montesano, M, Pesapane, F, Ferrari, F, Dominelli, V, Rotili, A, Meneghetti, L, Frassoni, S, Bagnardi, V, Sangalli, C, and Cassano, E
- Subjects
Cancer Research ,contrast-enhanced spectral mammography (CESM) ,breast carcinoma ,breast ,biopsy ,score ,Oncology - Abstract
Background: To create a predictive score of malignancy of a breast lesion based on the main contrast enhancement features ascertained by contrast-enhanced spectral mammography (CESM). Methods: In this single-centre prospective study, patients with suspicious breast lesions (BIRADS > 3) were enrolled between January 2013 and February 2022. All participants underwent CESM prior to breast biopsy, and eventually surgery. A radiologist with 20 years’ experience in breast imaging evaluated the presence or absence of enhancement and the following enhancement descriptors: intensity, pattern, margin, and ground glass. A score of 0 or 1 was given for each descriptor, depending on whether the enhancement characteristic was predictive of benignity or malignancy (both in situ and invasive). Then, an overall enhancement score ranging from 0 to 4 was obtained. The histological results were considered the gold standard in the evaluation of the relationship between enhancement patterns and malignancy. Results: A total of 321 women (median age: 51 years; range: 22–83) with 377 suspicious breast lesions were evaluated. Two hundred forty-nine lesions (66%) have malignant histological results (217 invasive and 32 in situ). Considering an overall enhancement score ≥ 2 as predictive of malignancy, we obtain an overall sensitivity of 92.4%; specificity of 89.8%; positive predictive value of 94.7%; and negative predictive value of 85.8%. Conclusions: Our proposed predictive score on the enhancement descriptors of CESM to predict the malignancy of a breast lesion shows excellent results and can help in early breast cancer diagnosis and in avoiding unnecessary biopsies.
- Published
- 2022
15. A Model to Predict Upstaging to Invasive Carcinoma in Patients Preoperatively Diagnosed with Low-Grade Ductal Carcinoma In Situ of the Breast
- Author
-
Vincenzo Bagnardi, Filippo Pesapane, P. Veronesi, Maria Pizzamiglio, Germana Lissidini, Anna Bozzini, Nicola Fusco, Matteo Lazzeroni, G. Farante, Luca Nicosia, Samuele Frassoni, Silvia Penco, Elham Sajjadi, Chiara Trentin, Cristiana Fodor, Enrico Cassano, Nicosia, L, Bozzini, A, Penco, S, Trentin, C, Pizzamiglio, M, Lazzeroni, M, Lissidini, G, Veronesi, P, Farante, G, Frassoni, S, Bagnardi, V, Fodor, C, Fusco, N, Sajjadi, E, Cassano, E, and Pesapane, F
- Subjects
In situ ,medicine.medical_specialty ,Cancer Research ,Biopsy ,Active surveillance ,Article ,general_medical_research ,Invasive breast carcinoma ,Ductal carcinoma in situ (DCIS) ,Medicine ,In patient ,ductal carcinoma in situ (DCIS) ,invasive breast carcinoma ,breast ,biopsy ,overtreatment ,active surveillance ,Breast ,skin and connective tissue diseases ,RC254-282 ,Invasive carcinoma ,medicine.diagnostic_test ,Overtreatment ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Ductal carcinoma ,medicine.disease ,Oncology ,Radiology ,business - Abstract
Simple Summary Surgical management is currently the main standard of care procedure used in order to treat ductal carcinoma in situ (DCIS) of the breast. Nevertheless, the survival benefit of surgical resection in patients with such lesions appears to be low, especially for low-grade DCIS. Low-grade DCIS typically exhibit a slow growth pattern and, in many cases, never fully develop into a clinically significant disease: discerning harmless lesions from potentially invasive ones could lead to avoid overtreatment in many patients. Nonetheless, up to 26% of patients with biopsy-proven DCIS can reveal a synchronous invasive carcinoma in surgical specimens. Here, we aimed to create a model of radiological and pathological criteria able to reduce the underestimation of vacuum assisted breast biopsy in DCIS, identifying patients at very low risk (e.g.
- Published
- 2022
16. Detection of Polyomavirus in Merkel cell carcinoma by immunohistochemistry: report of three cases
- Author
-
Vaira F, Nazzaro G, Filippo Pesapane, Brambilla L, Coggi A, Fanoni D, Venegoni L, Tourlaki A, Gianotti R, Berti E, Vaira, F, Nazzaro, G, Pesapane, F, Brambilla, L, Coggi, A, Fanoni, D, Venegoni, L, Tourlaki, A, Gianotti, R, and Berti, E
- Subjects
Aged, 80 and over ,Carcinoma, Merkel Cell ,Polyomavirus Infections ,Tumor Virus Infections ,Skin Neoplasms ,Merkel cell polyomavirus ,MED/35 - MALATTIE CUTANEE E VENEREE ,Humans ,Female ,Merkel cell carcinoma, polyomavirus ,Immunohistochemistry ,Aged - Abstract
Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine carcinoma of the skin, arising from pluripotent precursors of Merkel cells. The tumor most frequently affects head and neck of elderly patients. It increases with sun exposure and after immunosuppression and organ transplantation. Because of a possible viral association, interest in MCC has escalated. A new polyomavirus, Merkel cell polyomavirus (MCPyV), was identified and associated to MCC. In support of this hypothesis, we report three new clinical cases of MCC in which we detected MCPyV by immunohistochemistry and provide an update on current thinking about the MCC.
17. From theory to practice: Implementing next-generation sequencing and public health genomics in healthcare systems.
- Author
-
Horgan D, Pesapane F, Van der Buckle M, de Maria R, Dube F, Singh J, Ługowska I, Bayle A, Hofman P, Malapelle U, Hills T, Capoluongo ED, and Subbiah V
- Subjects
- Humans, Genomics methods, Public Health methods, Delivery of Health Care, High-Throughput Nucleotide Sequencing methods
- Abstract
If Europe's health systems make a conscious decision to increase their utilization of technology and techniques that can enhance prevention and expedite early-stage diagnosis, they can effectively address the growing challenges of disease. By embracing these advancements, these health systems can significantly improve their response to emerging health issues.However, at present the effective integration and exploitation of these opportunities remains hesitant and suboptimal, and health and health services underperform accordingly, with patients suffering from the continuing variations in diagnosis and access to innovation. This paper presents a comprehensive study that examines the current state of various influential disciplines and factors in European countries. It specifically focuses on the adoption of Next Generation Screening technologies and the development stage of Public Health Genomics. The assessment of these areas is presented in the context of a rapidly changing policy environment, which provides an opportunity for a fundamental reconsideration of how and where new tools can be integrated into healthcare systems and routine practices. Top of Form., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Denis HORGAN reports financial support and article publishing charges were provided by European Commission Directorate-General for Research and Innovation. Denis HORGAN reports a relationship with European Commission Directorate-General for Research and Innovation that includes: funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
18. The Picasso's skepticism on computer science and the dawn of generative AI: questions after the answers to keep "machines-in-the-loop".
- Author
-
Pesapane F, Cuocolo R, and Sardanelli F
- Subjects
- Humans, Radiology, Artificial Intelligence
- Abstract
Starting from Picasso's quote ("Computers are useless. They can only give you answers"), we discuss the introduction of generative artificial intelligence (AI), including generative adversarial networks (GANs) and transformer-based architectures such as large language models (LLMs) in radiology, where their potential in reporting, image synthesis, and analysis is notable. However, the need for improvements, evaluations, and regulations prior to clinical use is also clear. Integration of LLMs into clinical workflow needs cautiousness, to avoid or at least mitigate risks associated with false diagnostic suggestions. We highlight challenges in synthetic image generation, inherent biases in AI models, and privacy concerns, stressing the importance of diverse training datasets and robust data privacy measures. We examine the regulatory landscape, including the 2023 Executive Order on AI in the United States and the 2024 AI Act in the European Union, which set standards for AI applications in healthcare. This manuscript contributes to the field by emphasizing the necessity of maintaining the human element in medical procedures while leveraging generative AI, advocating for a "machines-in-the-loop" approach., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
19. Errors in Radiology: A Standard Review.
- Author
-
Pesapane F, Gnocchi G, Quarrella C, Sorce A, Nicosia L, Mariano L, Bozzini AC, Marinucci I, Priolo F, Abbate F, Carrafiello G, and Cassano E
- Abstract
Radiological interpretations, while essential, are not infallible and are best understood as expert opinions formed through the evaluation of available evidence. Acknowledging the inherent possibility of error is crucial, as it frames the discussion on improving diagnostic accuracy and patient care. A comprehensive review of error classifications highlights the complexity of diagnostic errors, drawing on recent frameworks to categorize them into perceptual and cognitive errors, among others. This classification underpins an analysis of specific error types, their prevalence, and implications for clinical practice. Additionally, we address the psychological impact of radiological practice, including the effects of mental health and burnout on diagnostic accuracy. The potential of artificial intelligence (AI) in mitigating errors is discussed, alongside ethical and regulatory considerations in its application. This research contributes to the body of knowledge on radiological errors, offering insights into preventive strategies and the integration of AI to enhance diagnostic practices. It underscores the importance of a nuanced understanding of errors in radiology, aiming to foster improvements in patient care and radiological accuracy.
- Published
- 2024
- Full Text
- View/download PDF
20. Radiologists' Communicative Role in Breast Cancer Patient Management: Beyond Diagnosis.
- Author
-
Mariano L, Nicosia L, Sorce A, Pesapane F, Coppini V, Grasso R, Monzani D, Pravettoni G, Mauri G, Venturini M, Pizzamiglio M, and Cassano E
- Abstract
In the landscape of cancer treatment, particularly in the realm of breast cancer management, effective communication emerges as a pivotal factor influencing patient outcomes. This article delves into the nuanced intricacies of communication skills, specifically spotlighting the strategies embraced by breast radiologists. By examining the ramifications of communication on patient experience, interdisciplinary collaboration, and legal ramifications, this study underscores the paramount importance of empathetic and comprehensive communication approaches. A special emphasis is placed on the utilization of the SPIKES protocol, a structured method for conveying sensitive health information, and the deployment of strategies for navigating challenging conversations. Furthermore, the work encompasses the significance of communication with caregivers, the integration of artificial intelligence, and the acknowledgement of patients' psychological needs. By adopting empathetic communication methodologies and fostering multidisciplinary collaboration, healthcare practitioners have the potential to enhance patient satisfaction, promote treatment adherence, and augment the overall outcomes within breast cancer diagnosis. This paper advocates for the implementation of guidelines pertaining to psychological support and the allocation of sufficient resources to ensure the provision of holistic and patient-centered cancer care. The article stresses the need for a holistic approach that addresses patients' emotional and psychological well-being alongside medical treatment. Through thoughtful and empathetic communication practices, healthcare providers can profoundly impact patient experiences and breast cancer journeys in a positive manner.
- Published
- 2024
- Full Text
- View/download PDF
21. Invasive lobular breast cancer: Focus on prevention, genetics, diagnosis, and treatment.
- Author
-
Corso G, Fusco N, Guerini-Rocco E, Leonardi MC, Criscitiello C, Zagami P, Nicolò E, Mazzarol G, La Vecchia C, Pesapane F, Zanzottera C, Tarantino P, Petitto S, Bianchi B, Massari G, Boato A, Sibilio A, Polizzi A, Curigliano G, De Scalzi AM, Lauria F, Bonanni B, Marabelli M, Rotili A, Nicosia L, Albini A, Calvello M, Mukhtar RA, Robson ME, Sacchini V, Rennert G, Galimberti V, Veronesi P, and Magnoni F
- Subjects
- Humans, Female, Breast Neoplasms diagnosis, Breast Neoplasms genetics, Breast Neoplasms therapy, Breast Neoplasms pathology, Breast Neoplasms prevention & control, Carcinoma, Lobular diagnosis, Carcinoma, Lobular therapy, Carcinoma, Lobular genetics, Carcinoma, Lobular pathology
- Abstract
Invasive lobular cancer (ILC) is the most common of the breast cancer special types, accounting for up to 15% of all breast malignancies. The distinctive biological features of ILC include the loss of the cell adhesion molecule E-cadherin, which drives the tumor's peculiar discohesive growth pattern, with cells arranged in single file and dispersed throughout the stroma. Typically, such tumors originate in the lobules, are more commonly bilateral compared to invasive ductal cancer (IDC) and require a more accurate diagnostic examination through imaging. They are luminal in molecular subtype, and exhibit estrogen and progesterone receptor positivity and HER2 negativity, thus presenting a more unpredictable response to neoadjuvant therapies. There has been a significant increase in research focused on this distinctive breast cancer subtype, including studies on its pathology, its clinical and surgical management, and the high-resolution definition of its genomic profile, as well as the development of new therapeutic perspectives. This review will summarize the heterogeneous pattern of this unique disease, focusing on challenges in its comprehensive clinical management and on future insights and research objectives., Competing Interests: Declaration of competing interest No financial/personal interest from all Authors with the exception of Prof. Giuseppe Curigliano., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
22. Non-contrast MRI and post-mastectomy silicone breast implant rupture: preventing false positive diagnoses.
- Author
-
Mazzocconi L, De Lorenzi F, Carbonaro R, Lorenzano V, Rotili A, Pesapane F, Signorelli G, Caldarella P, Corso G, Cassano E, and Veronesi P
- Abstract
Background: Breast implants are not lifelong, with implant rupture being the third leading cause of revisional surgery in augmented women. Noncontrast MRI is a reliable tool to assess implant integrity; however, false positive and false negative diagnoses have been reported due to an incorrect interpretation of MRI signs. This study aims to investigate the incidence of these misleading results, comparing MRI findings with intraoperative surgical observations and exploring signs of nonunivocal interpretation., Materials and Methods: Between March 2019 and October 2022, our hospital, a referral center for breast cancer care, conducted 139 breast MRI examinations to evaluate implant integrity. Surgical intervention was deemed necessary for patients diagnosed with suspected or confirmed implant rupture at MRI. Those patients who did not undergo any surgical procedure (63 cases) or had surgery at different institutes (11 cases) were excluded., Results: Among the 65 patients who underwent preoperative MRI and subsequent surgery at our institute, surgical findings confirmed the preoperative MRI diagnosis in 48 women. Notably, 17 women exhibited a discordance between MRI and surgical findings: three false negatives, 11 false positives and three possible ruptures not confirmed. Signs of nonunivocal or misleading interpretation were assessed on a patient-by-patient basis. The importance of obtaining detailed information about a patient's breast implant, including fill materials, number of lumens, manufacturer and shape, proved immensely beneficial for interpreting MRI signs accurately., Conclusion: Pre-MRI knowledge of implant details and a meticulous evaluation of non-univocal signs can aid radiologists in accurately assessing implant integrity, reducing the risk of unnecessary revisional surgeries, and potentially averting allegations of medical malpractice., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
23. CDH1 Genotype Exploration in Women With Hereditary Lobular Breast Cancer Phenotype.
- Author
-
Corso G, Marino E, Zanzottera C, Oliveira C, Bernard L, Macis D, Figueiredo J, Pereira J, Carneiro P, Massari G, Barberis M, De Scalzi AM, Taormina SV, Sajjadi E, Sangalli C, Gandini S, D'Ecclesiis O, Trovato CM, Rotili A, Pesapane F, Nicosia L, La Vecchia C, Galimberti V, Guerini-Rocco E, Bonanni B, and Veronesi P
- Subjects
- Humans, Female, Middle Aged, Prospective Studies, Adult, Genetic Predisposition to Disease, Carcinoma, Lobular genetics, Carcinoma, Lobular pathology, Longitudinal Studies, Genotype, Aged, Breast Neoplasms genetics, Cadherins genetics, Antigens, CD genetics, Germ-Line Mutation, Phenotype
- Abstract
Importance: Pathogenic or likely pathogenic (P/LP) germline CDH1 variants are associated with risk for diffuse gastric cancer and lobular breast cancer (LBC) in the so-called hereditary diffuse gastric cancer (HDGC) syndrome. However, in some circumstances, LBC can be the first manifestation of this syndrome in the absence of diffuse gastric cancer manifestation., Objectives: To evaluate the frequency of germline CDH1 variants in women with the hereditary LBC (HLBC) phenotype, somatic CDH1 gene inactivation in germline CDH1 variant carriers' tumor samples, and the association of genetic profiles with clinical-pathological data and survival., Design, Setting, and Participants: This single-center, longitudinal, prospective cohort study was conducted from January 1, 1997, to December 31, 2021, with follow-up until January 31, 2023. Women with LBC seen at the European Institute of Oncology were included. Testing for germline CDH1, BRCA1, and BRCA2 genes was performed. Somatic profiling was assessed for germline CDH1 carriers., Main Outcomes and Measures: Accurate estimates of prevalence of germline CDH1 variants among patients with HLBC and the association of somatic sequence alteration with HLBC syndrome. The Kaplan-Meier method and a multivariable Cox proportional hazards regression model were applied for overall and disease-free survival analysis., Results: Of 5429 cases of primary LBC, familial LBC phenotype accounted for 1867 (34.4%). A total of 394 women with LBC were tested, among whom 15 germline CDH1 variants in 15 unrelated families were identified. Among these variants, 6 (40.0%) were P/LP, with an overall frequency of 1.5% (6 of 394). Of the 6 probands with P/LP CDH1 LBC, 5 (83.3%) had a positive family history of BC and only 1 (16.7%) had sporadic juvenile early-onset LBC. No germline BRCA1 and BRCA2 variants were identified in CDH1 carriers. An inactivating CDH1 mechanism (second hit) was identified in 4 of 6 explored matched tumor samples (66.7%) in P/LP germline carriers. The P/LP CDH1 LBC variant carriers had a significantly lower age at diagnosis compared with the group carrying CDH1 variants of unknown significance or likely benign (42.5 [IQR, 38.3-43.0] vs 51.0 [IQR, 45.0-53.0] years; P = .03)., Conclusions and Relevance: In this cohort study, P/LP germline CDH1 variants were identified in individuals not fulfilling the classic clinical criteria for HDGC screening, suggesting that identification of these variants may provide a novel method to test women with LBC with early age at diagnosis and/or positive family history of BC.
- Published
- 2024
- Full Text
- View/download PDF
24. Patients' Perceptions and Attitudes to the Use of Artificial Intelligence in Breast Cancer Diagnosis: A Narrative Review.
- Author
-
Pesapane F, Giambersio E, Capetti B, Monzani D, Grasso R, Nicosia L, Rotili A, Sorce A, Meneghetti L, Carriero S, Santicchia S, Carrafiello G, Pravettoni G, and Cassano E
- Abstract
Breast cancer remains the most prevalent cancer among women worldwide, necessitating advancements in diagnostic methods. The integration of artificial intelligence (AI) into mammography has shown promise in enhancing diagnostic accuracy. However, understanding patient perspectives, particularly considering the psychological impact of breast cancer diagnoses, is crucial. This narrative review synthesizes literature from 2000 to 2023 to examine breast cancer patients' attitudes towards AI in breast imaging, focusing on trust, acceptance, and demographic influences on these views. Methodologically, we employed a systematic literature search across databases such as PubMed, Embase, Medline, and Scopus, selecting studies that provided insights into patients' perceptions of AI in diagnostics. Our review included a sample of seven key studies after rigorous screening, reflecting varied patient trust and acceptance levels towards AI. Overall, we found a clear preference among patients for AI to augment rather than replace the diagnostic process, emphasizing the necessity of radiologists' expertise in conjunction with AI to enhance decision-making accuracy. This paper highlights the importance of aligning AI implementation in clinical settings with patient needs and expectations, emphasizing the need for human interaction in healthcare. Our findings advocate for a model where AI augments the diagnostic process, underlining the necessity for educational efforts to mitigate concerns and enhance patient trust in AI-enhanced diagnostics.
- Published
- 2024
- Full Text
- View/download PDF
25. Comparison of long-term outcome between clinically high risk lobular versus ductal breast cancer: a propensity score matched study.
- Author
-
Magnoni F, Corso G, Maisonneuve P, Bianchi B, Accardo G, Sangalli C, Massari G, Rotili A, Nicosia L, Pesapane F, Montagna E, Mazzarol G, Galimberti V, Veronesi P, and Curigliano G
- Abstract
Background: Abemaciclib is currently approved for the adjuvant treatment of high-risk, lymph node (LN)-positive, hormone receptor (HR)-positive breast cancer (BC). In a real-world setting the clinicopathologic features of patients potentially eligible for adjuvant abemaciclib remain to be defined. There are conflicting data regarding the biological behavior and long-term outcomes across invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). In our study we retrospectively assessed the real-world data and long-term outcome of selected high-risk features ILC compared to IDC, according to the MonarchE trial inclusion criteria., Methods: We identified 15,071 patients who got surgery at the European Institute of Oncology for a first primary, non-metastatic, HR-positive, HER2-negative BC from 2000 to 2008. 11,981 (79.5%) patients had an IDC and 1524 (10.1%) an ILC. The remaining 1566 patients (10.4%) had either combined ductal and lobular breast cancer or another histological breast cancer subtype. According to the eligibility criteria of the MonarchE study, we identified two high-risk groups, based on high number of positive lymph nodes, large tumor size, or a high cellular proliferation as measured by tumor grade or biomarkers. Patients were matched by propensity score., Findings: A total of 2872 (21.3%) patients were selected as clinically high-risk, including 361/1524 ILC (23.7%) and 2511/11,981 IDC (21%). 322 high-risk ILC were matched with similar high-risk IDC. The median follow-up was 13.2 years for survival. In the matched set, invasive disease-free survival (IDFS) (log-rank P = 0.09) and overall survival (OS) (log-rank P = 0.48) were not statistically significantly different between the two histological groups. For IDC patients, the 5-year and 10-year IDFS rates (95% CI) were 77.7% (72.9-82.2) and 57.3% (51.7-63.1) respectively, compared to the 5-year and 10-year IDFS rates of ILC patients that were 75.5% (70.6-80.2) and 50.7% (45.0-56.6). The 5-year and 10-year distant relapse free survival (DRFS) rates were 80% (75.3-84.2) and 65.3% (59.8-70.7) in IDC cohort, compared to the 5-year and the 10-year DRFS rates of 78.7% (74.0-83.1) and 61.5% (55.9-67.1) in the ILC cohort. Such data match the recent outcomes efficacy results of the MonarchE control arm. More patients in the ILC (n = 17) than in the IDC group (n = 10) developed axillary recurrence. At multivariable analysis, stratified for specific clinical features, age <35 years, pT2-3, axillary involvement with more than 10 positive axillary nodes were found to be predictors of unfavorable IDFS and OS in the overall matched high-risk population., Interpretation: Findings from this matched cohort study reported similar IDFS and DRFS rates for high risk HR positive early BC when compared to the control arm overall IDFS and DRFS rates reported from the MonarchE trial. Our study demonstrated rates of concordant long-term outcome status beyond histologic subtype. These data support an escalation strategy for these two different histological entities when diagnosed with high-risk features. In our dataset approximately 21% rate of high-risk HR positive early BC patients are potentially eligible for adjuvant abemaciclib treatment., Funding: Umberto Veronesi Foundation., Competing Interests: Prof. Giuseppe Curigliano: Grants or contracts from any entity: Merck; Consulting fees: BMS, Roche, Pfizer, Novartis, Lilly, Astra Zeneca, Daichii Sankyo, Merck, Seagen, Ellipsis, Gilead, Menarini; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Lilly, Pfizer, Relay, Gilead, Novartis; Support for attending meetings and/or travel: Daichii Sankyo. Dr. Emilia Montagna: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Novartis., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
26. Evolving paradigms in breast cancer screening: Balancing efficacy, personalization, and equity.
- Author
-
Pesapane F, Rotili A, Raimondi S, Aurilio G, Lazzeroni M, Nicosia L, Latronico A, Pizzamiglio M, Cassano E, and Gandini S
- Subjects
- Humans, Female, Early Detection of Cancer methods, Radiologists, Incidence, Mammography methods, Mass Screening methods, Breast Neoplasms epidemiology
- Abstract
Breast cancer remains a significant global health challenge, with projections indicating a troubling increase in incidence. Breast cancer screening programs have long been hailed as life-saving initiatives, yet their true impact on mortality rates is a subject of ongoing debate. Screening poses the risk of false positives and the detection of indolent tumors, potentially leading to overtreatment. Bias factors, including lead time, length time, and selection biases, further complicate the assessment of screening efficacy. Recent studies suggest that AI-driven image analysis may revolutionize breast cancer screening, maintaining diagnostic accuracy while reducing radiologists' workload. However, the generalizability of these findings to diverse populations is a critical consideration. Personalized screening approaches and equitable access to advanced technologies are essential to mitigate disparities. In conclusion, the breast cancer screening landscape is evolving, emphasizing the need for risk stratification, appropriate imaging modalities, and a personalized approach to reduce overdiagnosis and focus on cancers with the potential to impact lives while prioritizing patient-centered care., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. This work was partially supported by the Italian Ministry of Health Ricerca Corrente 5 × 1000., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
27. Atypical Ductal Hyperplasia and Lobular In Situ Neoplasm: High-Risk Lesions Challenging Breast Cancer Prevention.
- Author
-
Nicosia L, Mariano L, Pellegrino G, Ferrari F, Pesapane F, Bozzini AC, Frassoni S, Bagnardi V, Pupo D, Mazzarol G, De Camilli E, Sangalli C, Venturini M, Pizzamiglio M, and Cassano E
- Abstract
This retrospective study investigates the histopathological outcomes, upgrade rates, and disease-free survival (DFS) of high-risk breast lesions, including atypical ductal hyperplasia (ADH or DIN1b) and lobular in situ neoplasms (LIN), following Vacuum-Assisted Breast Biopsy (VABB) and surgical excision. The study addresses the challenge posed by these lesions due to their association with synchronous or adjacent Breast Cancer (BC) and increased future BC risk. The research, comprising 320 patients who underwent stereotactic VABB, focuses on 246 individuals with a diagnosis of ADH (120) or LIN (126) observed at follow-up. Pathological assessments, categorized by the UK B-coding system, were conducted, and biopsy samples were compared with corresponding excision specimens to determine upgrade rates for in situ or invasive carcinoma. Surgical excision was consistently performed for diagnosed ADH or LIN. Finally, patient follow-ups were assessed and compared between LIN and ADH groups to identify recurrence signs, defined as histologically confirmed breast lesions on either the same or opposite side. The results reveal that 176 (71.5%) patients showed no upgrade post-surgery, with ADH exhibiting a higher upgrade rate to in situ pathology than LIN1 (Atypical Lobular Hyperplasia, ALH)/LIN2 (Low-Grade Lobular in situ Carcinoma, LCIS) (38% vs. 20%, respectively, p -value = 0.002). Considering only patients without upgrade, DFS at 10 years was 77%, 64%, and 72% for ADH, LIN1, and LIN2 patients, respectively ( p -value = 0.92). The study underscores the importance of a multidisciplinary approach, recognizing the evolving role of VABB. It emphasizes the need for careful follow-up, particularly for lobular lesions, offering valuable insights for clinicians navigating the complex landscape of high-risk breast lesions. The findings advocate for heightened awareness and vigilance in managing these lesions, contributing to the ongoing refinement of clinical strategies in BC care.
- Published
- 2024
- Full Text
- View/download PDF
28. Contrast-enhanced mammography BI-RADS: a case-based approach to radiology reporting.
- Author
-
Nicosia L, Battaglia O, Venturini M, Fontana F, Minenna M, Pesenti A, Budascu D, Pesapane F, Bozzini AC, Pizzamiglio M, Meneghetti L, Latronico A, Signorelli G, Mariano L, and Cassano E
- Abstract
Contrast-enhanced mammography (CEM) is a relatively recent diagnostic technique increasingly being utilized in clinical practice. Until recently, there was a lack of standardized reporting for CEM findings. However, this has changed with the publication of a supplement in the Breast Imaging Reporting and Data System (BI-RADS). A comprehensive understanding of CEM is essential for further enhancing its role in both screening and managing patients with breast malignancies. CEM can also be beneficial for problem-solving, improving the management of uncertain breast findings. Practitioners in this field should become more cognizant of how and when to employ this technique and interpret the various CEM findings. This paper aims to outline the key findings in the updated version of the BI-RADS specifically dedicated to CEM. Additionally, it will present some clinical cases commonly encountered in clinical practice.Critical relevance statement Standardized reporting and a thorough understanding of CEM findings are pivotal for advancing the role of CEM in screening and managing breast cancer patients. This standardization contributes significantly to integrating CEM as an essential component of daily clinical practice.Key points • A complete knowledge and understanding of the findings outlined in the new BI-RADS CEM are necessary for accurate reporting.• BI-RADS CEM supplement is intuitive and practical to use.• Standardization of the CEM findings enables more accurate patient management., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
29. Radiological Features of Male Breast Neoplasms: How to Improve the Management of a Rare Disease.
- Author
-
Nicosia L, Mariano L, Bozzini AC, Pesapane F, Bagnardi V, Frassoni S, Oriecuia C, Dominelli V, Latronico A, Palma S, Venturini M, Fontana F, Priolo F, Abiuso I, Sangalli C, and Cassano E
- Abstract
The primary aim of our study was to assess the main mammographic and ultrasonographic features of invasive male breast malignancies. The secondary aim was to evaluate whether a specific radiological presentation would be associated with a worse receptor profile. Radiological images (mammography and/or ultrasound) of all patients who underwent surgery for male invasive breast cancer in our institution between 2008 and 2023 were retrospectively analyzed by two breast radiologists in consensus. All significant features of radiological presentation known in the literature were re-evaluated. Fifty-six patients were selected. The mean age at surgery of patients was 69 years (range: 35-81); in 82% of cases (46 patients), the histologic outcome was invasive ductal carcinoma. A total of 28 out of 56 (50%) patients had preoperative mammography; in 9/28 cases (32%), we found a mass with microcalcifications on mammography. The mass presented high density in 25 out of 28 patients (89%); the mass showed irregular margins in 15/28 (54%) cases. A total of 46 out of 56 patients had preoperative ultrasounds. The lesion showed a solid mass in 41/46 (89%) cases. In 5/46 patients (11%), the lesion was a mass with a mixed (partly liquid-partly solid) structure. We did not find any statistically significant correlation between major types of radiological presentation and tumor receptor arrangement. Knowledge of the main radiologic presentation patterns of malignant male breast neoplasm can help better manage this type of disease, which is rare but whose incidence is increasing.
- Published
- 2024
- Full Text
- View/download PDF
30. Contrast-Enhanced Mammography (CEM) compared to Breast Magnetic Resonance (MRI) in the evaluation of breast lobular neoplasia.
- Author
-
Nicosia L, Rotili A, Pesapane F, Bozzini AC, Battaglia O, Pellegrino G, Fusco N, Porta FM, Frassoni S, Bagnardi V, Corso G, Sangalli C, and Cassano E
- Subjects
- Humans, Female, Retrospective Studies, Contrast Media, Mammography methods, Magnetic Resonance Imaging methods, Magnetic Resonance Spectroscopy, Sensitivity and Specificity, Breast Neoplasms diagnostic imaging, Breast Neoplasms surgery
- Abstract
Purpose: To compare the diagnostic performance (detection, assessment of correct disease extent and multifocality/centricity) of Contrast-Enhanced Mammography (CEM) Versus Breast Magnetic Resonance (MRI) in the study of lobular neoplasms., Methods: We retrospectively selected all the patients who underwent surgery for a lobular breast neoplasm, either an in situ or an invasive tumor, and had undergone both breast CEM and MRI examinations during the pre-surgical planning. Wilcoxon Signed Rank test was performed to assess the differences between size measurements using the different methods and the post-surgical pathological measurements, considered the gold standard. The agreement in identifying multifocality/multicentricity among the different methods and the pathology was assessed using the Kappa statistics., Results: We selected 19 patients, of which one presented a bilateral neoplasm. Then, the images of these 19 patients were analyzed, for a total of 52 malignant breast lesions. We found no significant differences between the post-surgical pathological size of the lesions and the calculated size with CEM and MRI (p-value of the difference respectively 0.71 and 0.47). In all 20 cases, neoplasm detection was possible both with CEM and MRI. CEM and MRI showed an excellent ability to identify multifocal and multicentric cases (K statistic equal to 0.93 for both the procedures), while K statistic was 0.11 and 0.59 for FFDM and US, respectively., Conclusion: The findings of this study suggest that CEM is a reliable imaging technique in the preoperative setting of patients with lobular neoplasm, with comparable results to breast MRI., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
31. Disparities in Breast Cancer Diagnostics: How Radiologists Can Level the Inequalities.
- Author
-
Pesapane F, Tantrige P, Rotili A, Nicosia L, Penco S, Bozzini AC, Raimondi S, Corso G, Grasso R, Pravettoni G, Gandini S, and Cassano E
- Abstract
Access to medical imaging is pivotal in healthcare, playing a crucial role in the prevention, diagnosis, and management of diseases. However, disparities persist in this scenario, disproportionately affecting marginalized communities, racial and ethnic minorities, and individuals facing linguistic or cultural barriers. This paper critically assesses methods to mitigate these disparities, with a focus on breast cancer screening. We underscore scientific mobility as a vital tool for radiologists to advocate for healthcare policy changes: it not only enhances diversity and cultural competence within the radiology community but also fosters international cooperation and knowledge exchange among healthcare institutions. Efforts to ensure cultural competency among radiologists are discussed, including ongoing cultural education, sensitivity training, and workforce diversification. These initiatives are key to improving patient communication and reducing healthcare disparities. This paper also highlights the crucial role of policy changes and legislation in promoting equal access to essential screening services like mammography. We explore the challenges and potential of teleradiology in improving access to medical imaging in remote and underserved areas. In the era of artificial intelligence, this paper emphasizes the necessity of validating its models across a spectrum of populations to prevent bias and achieve equitable healthcare outcomes. Finally, the importance of international collaboration is illustrated, showcasing its role in sharing insights and strategies to overcome global access barriers in medical imaging. Overall, this paper offers a comprehensive overview of the challenges related to disparities in medical imaging access and proposes actionable strategies to address these challenges, aiming for equitable healthcare delivery.
- Published
- 2023
- Full Text
- View/download PDF
32. Inter-reader agreement of breast magnetic resonance imaging and contrast-enhanced mammography in breast cancer diagnosis: a multi-reader retrospective study.
- Author
-
Pesapane F, Nicosia L, Tantrige P, Schiaffino S, Liguori A, Montesano M, Bozzini A, Rotili A, Cellina M, Orsi M, Penco S, Pizzamiglio M, Carrafiello G, and Cassano E
- Abstract
Objective: Breast magnetic resonance imaging (MRI) and contrast-enhanced mammography (CEM) are nowadays used in breast imaging but studies about their inter-reader agreement are lacking. Therefore, we compared the inter-reader agreement of CEM and MRI in breast cancer diagnosis in the same patients., Methods: Breast MRI and CEM exams performed in a single center (09/2020-09/2021) for an IRB-approved study were retrospectively and independently evaluated by four radiologists of two different centers with different levels of experience who were blinded to the clinical and other imaging data. The reference standard was the histological diagnosis or at least 1-year negative imaging follow-up. Inter-reader agreement was examined using Cohen's and Fleiss' kappa (κ) statistics and compared with the Wald test., Results: Of the 750 patients, 395 met inclusion criteria (44.5 ± 14 years old), with 752 breasts available for CEM and MRI. Overall agreement was moderate (κ = 0.60) for MRI and substantial (κ = 0.74) for CEM. For expert readers, the agreement was substantial (κ = 0.77) for MRI and almost perfect (κ = 0.82) for CEM; for non-expert readers was fair (κ = 0.39); and for MRI and moderate (κ = 0.57) for CEM. Pairwise agreement between expert readers and non-expert readers was moderate (κ = 0.50) for breast MRI and substantial (κ = 0.74) for CEM and it showed a statistically superior agreement of the expert over the non-expert readers only for MRI (p = 0.011) and not for CEM (p = 0.062)., Conclusions: The agreement of CEM was superior to that of MRI (p = 0.012), including for both expert (p = 0.031) and non-expert readers (p = 0.005)., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
33. Advances in breast cancer risk modeling: integrating clinics, imaging, pathology and artificial intelligence for personalized risk assessment.
- Author
-
Pesapane F, Battaglia O, Pellegrino G, Mangione E, Petitto S, Fiol Manna ED, Cazzaniga L, Nicosia L, Lazzeroni M, Corso G, Fusco N, and Cassano E
- Subjects
- Humans, Female, Artificial Intelligence, Breast diagnostic imaging, Mammography methods, Risk Assessment, Risk Factors, Early Detection of Cancer methods, Breast Neoplasms diagnostic imaging, Breast Neoplasms genetics
- Abstract
Breast cancer risk models represent the likelihood of developing breast cancer based on risk factors. They enable personalized interventions to improve screening programs. Radiologists identify mammographic density as a significant risk factor and test new imaging techniques. Pathologists provide data for risk assessment. Clinicians conduct individual risk assessments and adopt prevention strategies for high-risk subjects. Tumor genetic testing guides personalized screening and treatment decisions. Artificial intelligence in mammography integrates imaging, clinical, genetic and pathological data to develop risk models. Emerging imaging technologies, genetic testing and molecular profiling improve risk model accuracy. The complexity of the disease, limited data availability and model inputs are discussed. A multidisciplinary approach is essential for earlier detection and improved outcomes.
- Published
- 2023
- Full Text
- View/download PDF
34. Enhancing Breast Imaging Practices: Addressing False-Positive Findings, Personalization, and Equitable Access.
- Author
-
Pesapane F and Cassano E
- Subjects
- Humans, Female, Early Detection of Cancer methods, False Positive Reactions, Diagnostic Imaging, Breast Neoplasms diagnostic imaging
- Published
- 2023
- Full Text
- View/download PDF
35. Updates on Breast Cancer.
- Author
-
Pesapane F, Nicosia L, and Cassano E
- Abstract
This collection of 18 articles, comprising 12 original studies, 1 systematic review, and 5 reviews, is a collaborative effort by distinguished experts in breast cancer research, and it has been edited by Dr [...].
- Published
- 2023
- Full Text
- View/download PDF
36. Deep learning performance for detection and classification of microcalcifications on mammography.
- Author
-
Pesapane F, Trentin C, Ferrari F, Signorelli G, Tantrige P, Montesano M, Cicala C, Virgoli R, D'Acquisto S, Nicosia L, Origgi D, and Cassano E
- Subjects
- Humans, Female, Artificial Intelligence, Retrospective Studies, Mammography, Deep Learning, Calcinosis, Breast Neoplasms
- Abstract
Background: Breast cancer screening through mammography is crucial for early detection, yet the demand for mammography services surpasses the capacity of radiologists. Artificial intelligence (AI) can assist in evaluating microcalcifications on mammography. We developed and tested an AI model for localizing and characterizing microcalcifications., Methods: Three expert radiologists annotated a dataset of mammograms using histology-based ground truth. The dataset was partitioned for training, validation, and testing. Three neural networks (AlexNet, ResNet18, and ResNet34) were trained and evaluated using specific metrics including receiver operating characteristics area under the curve (AUC), sensitivity, and specificity. The reported metrics were computed on the test set (10% of the whole dataset)., Results: The dataset included 1,000 patients aged 21-73 years and 1,986 mammograms (180 density A, 220 density B, 380 density C, and 220 density D), with 389 malignant and 611 benign groups of microcalcifications. AlexNet achieved the best performance with 0.98 sensitivity, 0.89 specificity of, and 0.98 AUC for microcalcifications detection and 0.85 sensitivity, 0.89 specificity, and 0.94 AUC of for microcalcifications classification. For microcalcifications detection, ResNet18 and ResNet34 achieved 0.96 and 0.97 sensitivity, 0.91 and 0.90 specificity and 0.98 and 0.98 AUC, retrospectively. For microcalcifications classification, ResNet18 and ResNet34 exhibited 0.75 and 0.84 sensitivity, 0.85 and 0.84 specificity, and 0.88 and 0.92 AUC, respectively., Conclusions: The developed AI models accurately detect and characterize microcalcifications on mammography., Relevance Statement: AI-based systems have the potential to assist radiologists in interpreting microcalcifications on mammograms. The study highlights the importance of developing reliable deep learning models possibly applied to breast cancer screening., Key Points: • A novel AI tool was developed and tested to aid radiologists in the interpretation of mammography by accurately detecting and characterizing microcalcifications. • Three neural networks (AlexNet, ResNet18, and ResNet34) were trained, validated, and tested using an annotated dataset of 1,000 patients and 1,986 mammograms. • The AI tool demonstrated high accuracy in detecting/localizing and characterizing microcalcifications on mammography, highlighting the potential of AI-based systems to assist radiologists in the interpretation of mammograms., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
37. A Pictorial Exploration of Mammary Paget Disease: Insights and Perspectives.
- Author
-
Mariano L, Nicosia L, Pupo D, Olivieri AM, Scolari S, Pesapane F, Latronico A, Bozzini AC, Fusco N, Blanco MC, Mazzarol G, Corso G, Galimberti VE, Venturini M, Pizzamiglio M, and Cassano E
- Abstract
Mammary Paget disease (MPD) is a rare condition primarily affecting adult women, characterized by unilateral skin changes in the nipple-areolar complex (NAC) and frequently associated with underlying breast carcinoma. Histologically, MPD is identified by large intraepidermal epithelial cells (Paget cells) with distinct characteristics. Immunohistochemical profiles aid in distinguishing MPD from other skin conditions. Clinical evaluation and imaging techniques, including magnetic resonance imaging (MRI), are recommended if MPD is suspected, although definitive diagnosis always requires histological examination. This review delves into the historical context, epidemiology, pathogenesis, clinical manifestations, and diagnosis of MPD, emphasizing the need for early detection. The classification of MPD based on pathogenesis is explored, shedding light on its varied presentations. Treatment options, including mastectomy and breast-conserving surgery, are discussed with clear guidelines for different scenarios. Adjuvant therapies are considered, particularly in cases with underlying breast cancer. Prognostic factors are outlined, underlining the importance of early intervention. Looking to the future, emerging techniques, like liquid biopsy, new immunohistochemical and molecular markers, and artificial intelligence-based image analysis, hold the potential to transform MPD diagnosis and treatment. These innovations offer hope for early detection and improved patient care, though validation through large-scale clinical trials is needed.
- Published
- 2023
- Full Text
- View/download PDF
38. The potential role of contrast-enhanced mammography in downgrading BI-RADS 4 lesions: A balanced perspective.
- Author
-
Pesapane F, Rotili A, Dominelli V, and Cassano E
- Subjects
- Humans, Female, Breast diagnostic imaging, Retrospective Studies, Mammography, Breast Neoplasms diagnostic imaging
- Abstract
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
- Published
- 2023
- Full Text
- View/download PDF
39. Breast Imaging Reporting and Data System and Contrast Enhancement Mammography: Lesion Conspicuity Likelihood of Malignancy and Relationship With Breast Tumor Receptor Status.
- Author
-
Nicosia L, Bozzini AC, Palma S, Pesapane F, Meneghetti L, Pizzamiglio M, Abbate F, Latronico A, Bagnardi V, Frassoni S, Sangalli C, and Cassano E
- Subjects
- Humans, Middle Aged, Female, Mammography methods, Biopsy, Radiologists, Contrast Media, Breast Neoplasms pathology
- Abstract
Rationale and Objectives: The new version of the Contrast Enhanced Mammography (CEM) Breast imaging Reporting and Data System (BIRADs) encourages investigations of a new enhancement descriptor: "Lesion Conspicuity" (LC). The study aims to assess the diagnostic performance and the relationship with the receptor profile of this new enhancement descriptor., Materials and Methods: Three hundred twenty-five patients with 381 breast lesions who underwent CEM before histological assessmentwere selected. Four radiologists, blinded to each other, categorized LC into the following levels: absent, low, moderate, and high. Considering moderate and high evaluations as predictive of malignancy, the diagnostic performance of CEM was calculated using histological results of the biopsy as the gold standard. The association between LC values and the receptor profile of the neoplasms was also evaluated., Results: The median age at the CEM examination was 50 years (IQR: 45-59). Considering the value of LC of the most experienced radiologist with the interpretation of Low Energy images (LE), we obtained a sensitivity (SE) of 91.9% (95% CI: 88.6%-95.2%) and a specificity (SP) of 67.2% (95% CI: 58.9%-75.5%). An association between "high" lesion conspicuity with ER/PgR not expressed (p = 0.025), with Ki-67>20% (p = 0.033), and with Grading G3 (p = 0.020) was observed., Conclusion: The new feature of enhancement, "Lesion Conspicuity", demonstrated satisfactory performance in predicting the malignancy of lesions and significant correlation with the receptor profile of malignant breast neoplasms., Competing Interests: Declaration of Competing Interest This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors., (Copyright © 2023 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
40. Advancements in Standardizing Radiological Reports: A Comprehensive Review.
- Author
-
Pesapane F, Tantrige P, De Marco P, Carriero S, Zugni F, Nicosia L, Bozzini AC, Rotili A, Latronico A, Abbate F, Origgi D, Santicchia S, Petralia G, Carrafiello G, and Cassano E
- Subjects
- Humans, Radiography, Communication, Language, Workflow, Radiology
- Abstract
Standardized radiological reports stimulate debate in the medical imaging field. This review paper explores the advantages and challenges of standardized reporting. Standardized reporting can offer improved clarity and efficiency of communication among radiologists and the multidisciplinary team. However, challenges include limited flexibility, initially increased time and effort, and potential user experience issues. The efforts toward standardization are examined, encompassing the establishment of reporting templates, use of common imaging lexicons, and integration of clinical decision support tools. Recent technological advancements, including multimedia-enhanced reporting and AI-driven solutions, are discussed for their potential to improve the standardization process. Organizations such as the ACR, ESUR, RSNA, and ESR have developed standardized reporting systems, templates, and platforms to promote uniformity and collaboration. However, challenges remain in terms of workflow adjustments, language and format variability, and the need for validation. The review concludes by presenting a set of ten essential rules for creating standardized radiology reports, emphasizing clarity, consistency, and adherence to structured formats.
- Published
- 2023
- Full Text
- View/download PDF
41. Future Directions in the Assessment of Axillary Lymph Nodes in Patients with Breast Cancer.
- Author
-
Pesapane F, Mariano L, Magnoni F, Rotili A, Pupo D, Nicosia L, Bozzini AC, Penco S, Latronico A, Pizzamiglio M, Corso G, and Cassano E
- Subjects
- Humans, Female, Lymphatic Metastasis pathology, Artificial Intelligence, Lymph Nodes pathology, Sentinel Lymph Node Biopsy methods, Lymph Node Excision, Axilla, Breast Neoplasms diagnostic imaging, Breast Neoplasms drug therapy
- Abstract
Background and Objectives : Breast cancer (BC) is a leading cause of morbidity and mortality worldwide, and accurate assessment of axillary lymph nodes (ALNs) is crucial for patient management and outcomes. We aim to summarize the current state of ALN assessment techniques in BC and provide insights into future directions. Materials and Methods : This review discusses various imaging techniques used for ALN evaluation, including ultrasound, computed tomography, magnetic resonance imaging, and positron emission tomography. It highlights advancements in these techniques and their potential to improve diagnostic accuracy. The review also examines landmark clinical trials that have influenced axillary management, such as the Z0011 trial and the IBCSG 23-01 trial. The role of artificial intelligence (AI), specifically deep learning algorithms, in improving ALN assessment is examined. Results : The review outlines the key findings of these trials, which demonstrated the feasibility of avoiding axillary lymph node dissection (ALND) in certain patient populations with low sentinel lymph node (SLN) burden. It also discusses ongoing trials, including the SOUND trial, which investigates the use of axillary ultrasound to identify patients who can safely avoid sentinel lymph node biopsy (SLNB). Furthermore, the potential of emerging techniques and the integration of AI in enhancing ALN assessment accuracy are presented. Conclusions : The review concludes that advancements in ALN assessment techniques have the potential to improve patient outcomes by reducing surgical complications while maintaining accurate disease staging. However, challenges such as standardization of imaging protocols and interpretation criteria need to be addressed. Future research should focus on large-scale clinical trials to validate emerging techniques and establish their efficacy and cost-effectiveness. Over-all, this review provides valuable insights into the current status and future directions of ALN assessment in BC, highlighting opportunities for improving patient care.
- Published
- 2023
- Full Text
- View/download PDF
42. An Unenhanced Breast MRI Protocol Based on Diffusion-Weighted Imaging: A Retrospective Single-Center Study on High-Risk Population for Breast Cancer.
- Author
-
Rotili A, Pesapane F, Signorelli G, Penco S, Nicosia L, Bozzini A, Meneghetti L, Zanzottera C, Mannucci S, Bonanni B, and Cassano E
- Abstract
Purpose: This study aimed to investigate the use of contrast-free magnetic resonance imaging (MRI) as an innovative screening method for detecting breast cancer in high-risk asymptomatic women. Specifically, the researchers evaluated the diagnostic performance of diffusion-weighted imaging (DWI) in this population., Methods: MR images from asymptomatic women, carriers of a germline mutation in either the BRCA1 or BRCA2 gene, collected in a single center from January 2019 to December 2021 were retrospectively evaluated. A radiologist with experience in breast imaging (R1) and a radiology resident (R2) independently evaluated DWI/ADC maps and, in case of doubts, T2-WI. The standard of reference was the pathological diagnosis through biopsy or surgery, or ≥1 year of clinical and radiological follow-up. Diagnostic performances were calculated for both readers with a 95% confidence interval (CI). The agreement was assessed using Cohen's kappa (κ) statistics., Results: Out of 313 women, 145 women were included (49.5 ± 12 years), totaling 344 breast MRIs with DWI/ADC maps. The per-exam cancer prevalence was 11/344 (3.2%). The sensitivity was 8/11 (73%; 95% CI: 46-99%) for R1 and 7/11 (64%; 95% CI: 35-92%) for R2. The specificity was 301/333 (90%; 95% CI: 87-94%) for both readers. The diagnostic accuracy was 90% for both readers. R1 recalled 40/344 exams (11.6%) and R2 recalled 39/344 exams (11.3%). Inter-reader reproducibility between readers was in moderate agreement (κ = 0.43)., Conclusions: In female carriers of a BRCA1/2 mutation, breast DWI supplemented with T2-WI allowed breast cancer detection with high sensitivity and specificity by a radiologist with extensive experience in breast imaging, which is comparable to other screening tests. The findings suggest that DWI and T2-WI have the potential to serve as a stand-alone method for unenhanced breast MRI screening in a selected population, opening up new perspectives for prospective trials.
- Published
- 2023
- Full Text
- View/download PDF
43. History of Mammography: Analysis of Breast Imaging Diagnostic Achievements over the Last Century.
- Author
-
Nicosia L, Gnocchi G, Gorini I, Venturini M, Fontana F, Pesapane F, Abiuso I, Bozzini AC, Pizzamiglio M, Latronico A, Abbate F, Meneghetti L, Battaglia O, Pellegrino G, and Cassano E
- Abstract
Breast cancer is the most common forms of cancer and a leading cause of mortality in women. Early and correct diagnosis is, therefore, essential to save lives. The development of diagnostic imaging applied to the breast has been impressive in recent years and the most used diagnostic test in the world is mammography, a low-dose X-ray technique used for imaging the breast. In the first half of the 20th century, the diagnosis was in practice only clinical, with consequent diagnostic delay and an unfavorable prognosis in the short term. The rise of organized mammography screening has led to a remarkable reduction in mortality through the early detection of breast malignancies. This historical review aims to offer a complete panorama of the development of mammography and breast imaging during the last century. Through this study, we want to understand the foundations of the pillar of radiology applied to the breast through to the most modern applications such as contrast-enhanced mammography (CEM), artificial intelligence, and radiomics. Understanding the history of the development of diagnostic imaging applied to the breast can help us understand how to better direct our efforts toward an increasingly personalized and effective diagnostic approach. The ultimate goal of imaging applied to the detection of breast malignancies should be to reduce mortality from this type of disease as much as possible. With this paper, we want to provide detailed documentation of the main steps in the evolution of breast imaging for the diagnosis of breast neoplasms; we also want to open up new scenarios where the possible current and future applications of imaging are aimed at being more precise and personalized.
- Published
- 2023
- Full Text
- View/download PDF
44. Breast Digital Tomosynthesis versus Contrast-Enhanced Mammography: Comparison of Diagnostic Application and Radiation Dose in a Screening Setting.
- Author
-
Nicosia L, Bozzini AC, Pesapane F, Rotili A, Marinucci I, Signorelli G, Frassoni S, Bagnardi V, Origgi D, De Marco P, Abiuso I, Sangalli C, Balestreri N, Corso G, and Cassano E
- Abstract
This study aims to evaluate the Average Glandular Dose (AGD) and diagnostic performance of CEM versus Digital Mammography (DM) as well as versus DM plus one-view Digital Breast Tomosynthesis (DBT), which were performed in the same patients at short intervals of time. A preventive screening examination in high-risk asymptomatic patients between 2020 and 2022 was performed with two-view Digital Mammography (DM) projections (Cranio Caudal and Medio Lateral) plus one Digital Breast Tomosynthesis (DBT) projection (mediolateral oblique, MLO) in a single session examination. For all patients in whom we found a suspicious lesion by using DM + DBT, we performed (within two weeks) a CEM examination. AGD and compression force were compared between the diagnostic methods. All lesions identified by DM + DBT were biopsied; then, we assessed whether lesions found by DBT were also highlighted by DM alone and/or by CEM. We enrolled 49 patients with 49 lesions in the study. The median AGD was lower for DM alone than for CEM (3.41 mGy vs. 4.24 mGy, p = 0.015). The AGD for CEM was significantly lower than for the DM plus one single projection DBT protocol (4.24 mGy vs. 5.55 mGy, p < 0.001). We did not find a statistically significant difference in the median compression force between the CEM and DM + DBT. DM + DBT allows the identification of one more invasive neoplasm one in situ lesion and two high-risk lesions, compared to DM alone. The CEM, compared to DM + DBT, failed to identify only one of the high-risk lesions. According to these results, CEM could be used in the screening of asymptomatic high-risk patients.
- Published
- 2023
- Full Text
- View/download PDF
45. How Radiomics Can Improve Breast Cancer Diagnosis and Treatment.
- Author
-
Pesapane F, De Marco P, Rapino A, Lombardo E, Nicosia L, Tantrige P, Rotili A, Bozzini AC, Penco S, Dominelli V, Trentin C, Ferrari F, Farina M, Meneghetti L, Latronico A, Abbate F, Origgi D, Carrafiello G, and Cassano E
- Abstract
Recent technological advances in the field of artificial intelligence hold promise in addressing medical challenges in breast cancer care, such as early diagnosis, cancer subtype determination and molecular profiling, prediction of lymph node metastases, and prognostication of treatment response and probability of recurrence. Radiomics is a quantitative approach to medical imaging, which aims to enhance the existing data available to clinicians by means of advanced mathematical analysis using artificial intelligence. Various published studies from different fields in imaging have highlighted the potential of radiomics to enhance clinical decision making. In this review, we describe the evolution of AI in breast imaging and its frontiers, focusing on handcrafted and deep learning radiomics. We present a typical workflow of a radiomics analysis and a practical "how-to" guide. Finally, we summarize the methodology and implementation of radiomics in breast cancer, based on the most recent scientific literature to help researchers and clinicians gain fundamental knowledge of this emerging technology. Alongside this, we discuss the current limitations of radiomics and challenges of integration into clinical practice with conceptual consistency, data curation, technical reproducibility, adequate accuracy, and clinical translation. The incorporation of radiomics with clinical, histopathological, and genomic information will enable physicians to move forward to a higher level of personalized management of patients with breast cancer.
- Published
- 2023
- Full Text
- View/download PDF
46. Contrast-Enhanced Spectral Mammography in the Evaluation of Breast Microcalcifications: Controversies and Diagnostic Management.
- Author
-
Nicosia L, Bozzini AC, Signorelli G, Palma S, Pesapane F, Frassoni S, Bagnardi V, Pizzamiglio M, Farina M, Trentin C, Penco S, Meneghetti L, Sangalli C, and Cassano E
- Abstract
The aim of this study was to evaluate the diagnostic performance of contrast-enhanced spectral mammography (CESM) in predicting breast lesion malignancy due to microcalcifications compared to lesions that present with other radiological findings. Three hundred and twenty-one patients with 377 breast lesions that underwent CESM and histological assessment were included. All the lesions were scored using a 4-point qualitative scale according to the degree of contrast enhancement at the CESM examination. The histological results were considered the gold standard. In the first analysis, enhancement degree scores of 2 and 3 were considered predictive of malignity. The sensitivity (SE) and positive predictive value (PPV) were significative lower for patients with lesions with microcalcifications without other radiological findings (SE = 53.3% vs. 82.2%, p -value < 0.001 and PPV = 84.2% vs. 95.2%, p -value = 0.049, respectively). On the contrary, the specificity (SP) and negative predictive value (NPV) were significative higher among lesions with microcalcifications without other radiological findings (SP = 95.8% vs. 84.2%, p -value = 0.026 and NPV = 82.9% vs. 55.2%, p -value < 0.001, respectively). In a second analysis, degree scores of 1, 2, and 3 were considered predictive of malignity. The SE (80.0% vs. 96.8%, p -value < 0.001) and PPV (70.6% vs. 88.3%, p -value: 0.005) were significantly lower among lesions with microcalcifications without other radiological findings, while the SP (85.9% vs. 50.9%, p -value < 0.001) was higher. The enhancement of microcalcifications has low sensitivity in predicting malignancy. However, in certain controversial cases, the absence of CESM enhancement due to its high negative predictive value can help to reduce the number of biopsies for benign lesions.
- Published
- 2023
- Full Text
- View/download PDF
47. Prediction of the Malignancy of a Breast Lesion Detected on Breast Ultrasound: Radiomics Applied to Clinical Practice.
- Author
-
Nicosia L, Pesapane F, Bozzini AC, Latronico A, Rotili A, Ferrari F, Signorelli G, Raimondi S, Vignati S, Gaeta A, Bellerba F, Origgi D, De Marco P, Castiglione Minischetti G, Sangalli C, Montesano M, Palma S, and Cassano E
- Abstract
The study aimed to evaluate the performance of radiomics features and one ultrasound CAD (computer-aided diagnosis) in the prediction of the malignancy of a breast lesion detected with ultrasound and to develop a nomogram incorporating radiomic score and available information on CAD performance, conventional Breast Imaging Reporting and Data System evaluation (BI-RADS), and clinical information. Data on 365 breast lesions referred for breast US with subsequent histologic analysis between January 2020 and March 2022 were retrospectively collected. Patients were randomly divided into a training group ( n = 255) and a validation test group ( n = 110). A radiomics score was generated from the US image. The CAD was performed in a subgroup of 209 cases. The radiomics score included seven radiomics features selected with the LASSO logistic regression model. The multivariable logistic model incorporating CAD performance, BI-RADS evaluation, clinical information, and radiomic score as covariates showed promising results in the prediction of the malignancy of breast lesions: Area under the receiver operating characteristic curve, [AUC]: 0.914; 95% Confidence Interval, [CI]: 0.876-0.951. A nomogram was developed based on these results for possible future applications in clinical practice.
- Published
- 2023
- Full Text
- View/download PDF
48. The Use of Artificial Intelligence (AI) in the Radiology Field: What Is the State of Doctor-Patient Communication in Cancer Diagnosis?
- Author
-
Derevianko A, Pizzoli SFM, Pesapane F, Rotili A, Monzani D, Grasso R, Cassano E, and Pravettoni G
- Abstract
Background: In the past decade, interest in applying Artificial Intelligence (AI) in radiology to improve diagnostic procedures increased. AI has potential benefits spanning all steps of the imaging chain, from the prescription of diagnostic tests to the communication of test reports. The use of AI in the field of radiology also poses challenges in doctor-patient communication at the time of the diagnosis. This systematic review focuses on the patient role and the interpersonal skills between patients and physicians when AI is implemented in cancer diagnosis communication., Methods: A systematic search was conducted on PubMed, Embase, Medline, Scopus, and PsycNet from 1990 to 2021. The search terms were: ("artificial intelligence" or "intelligence machine") and "communication" "radiology" and "oncology diagnosis". The PRISMA guidelines were followed., Results: 517 records were identified, and 5 papers met the inclusion criteria and were analyzed. Most of the articles emphasized the success of the technological support of AI in radiology at the expense of patient trust in AI and patient-centered communication in cancer disease. Practical implications and future guidelines were discussed according to the results., Conclusions: AI has proven to be beneficial in helping clinicians with diagnosis. Future research may improve patients' trust through adequate information about the advantageous use of AI and an increase in medical compliance with adequate training on doctor-patient diagnosis communication.
- Published
- 2023
- Full Text
- View/download PDF
49. Diagnostic performance of image-guided vacuum-assisted breast biopsy after neoadjuvant therapy for breast cancer: prospective pilot study.
- Author
-
Rossi EMC, Invento A, Pesapane F, Pagan E, Bagnardi V, Fusco N, Venetis K, Dominelli V, Trentin C, Cassano E, Gilardi L, Mazza M, Lazzeroni M, De Lorenzi F, Caldarella P, De Scalzi A, Girardi A, Sangalli C, Alberti L, Sacchini V, Galimberti V, and Veronesi P
- Subjects
- Humans, Adult, Middle Aged, Female, Pilot Projects, Prospective Studies, Neoadjuvant Therapy, Positron Emission Tomography Computed Tomography, Breast diagnostic imaging, Breast pathology, Image-Guided Biopsy methods, Breast Neoplasms diagnostic imaging, Breast Neoplasms surgery
- Abstract
Background: Image-guided vacuum-assisted breast biopsy (VABB) of the tumour bed, performed after neoadjuvant therapy, is increasingly being used to assess residual cancer and to potentially identify to identify pathological complete response (pCR). In this study, the accuracy of preoperative VABB specimens was assessed and compared with surgical specimens in patients with triple-negative or human epidermal growth factor receptor 2 (HER2)-positive invasive ductal breast cancer after neoadjuvant therapy. As a secondary endpoint, the performance of contrast-enhanced MRI of the breast and PET-CT for response prediction was assessed., Methods: This single-institution prospective pilot study enrolled patients from April 2018 to April 2021 with a complete response on imaging (iCR) who subsequently underwent VABB before surgery. Those with a pCR at VABB were included in the primary analysis of the accuracy of VABB. The performance of imaging (MRI and PET-CT) was analysed for prediction of a pCR considering both patients with an iCR and those with residual disease at postneoadjuvant therapy imaging., Results: Twenty patients were included in the primary analysis. The median age was 44 (range 35-51) years. At surgery, 18 of 20 patients showed a complete response (accuracy 90 (95 per cent exact c.i. 68 to 99) per cent). Only two patients showed residual ductal intraepithelial neoplasia of grade 2 and 3 respectively. In the secondary analysis, accuracy was similar for MRI and PET-CT (77 versus 78 per cent; P = 0.76)., Conclusion: VABB in patients with an iCR might be a promising method to select patients for de-escalation of surgical treatment in triple-negative or HER2-positive breast cancer. The present results support such an approach and should inform the design of future trials on de-escalation of surgery., (© The Author(s) 2022. Published by Oxford University Press on behalf of BJS Society Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
50. Women's perceptions and attitudes to the use of AI in breast cancer screening: a survey in a cancer referral centre.
- Author
-
Pesapane F, Rotili A, Valconi E, Agazzi GM, Montesano M, Penco S, Nicosia L, Bozzini A, Meneghetti L, Latronico A, Pizzamiglio M, Rossero E, Gaeta A, Raimondi S, Pizzoli SFM, Grasso R, Carrafiello G, Pravettoni G, and Cassano E
- Subjects
- Humans, Female, Artificial Intelligence, Prospective Studies, Pilot Projects, Mammography, Surveys and Questionnaires, Referral and Consultation, Early Detection of Cancer, Breast Neoplasms diagnostic imaging
- Abstract
Objective: Although breast cancer screening can benefit from Artificial Intelligence (AI), it is still unknown whether, to which extent or under which conditions, the use of AI is going to be accepted by the general population. The aim of our study is to evaluate what the females who are eligible for breast cancer screening know about AI and how they perceive such innovation., Methods: We used a prospective survey consisting of a 11-multiple-choice questionnaire evaluating statistical associations with Chi-Square-test or Fisher-exact-test. Multinomial-logistic-regression was performed on items with more than two response categories. Odds ratio (OR) with 95% CI were computed to estimate the probability of a specific response according to patient's characteristics., Results: In the 800 analysed questionnaires, 51% of respondents confirmed to have knowledge of AI. Of these, 88% expressed a positive opinion about its use in medicine. Non-Italian respondents were associated with the belief of having a deep awareness about AI more often than Italian respondents (OR = 1.91;95% CI[1.10-3.33]). Higher education level was associated with better opinions on the use of AI in medicine (OR = 4.69;95% CI[1.36-16.12]). According to 94% of respondents, the radiologists should always produce their own report on mammograms, whilst 77% agreed that AI should be used as a second reader. Most respondents (52%) considered that both the software developer and the radiologist should be held accountable for AI errors., Conclusions: Most of the females undergoing screening in our Institute approve the introduction of AI, although only as a support to radiologist, and not in substitution thereof. Yet, accountability in case of AI errors is still unsolved. advances in knowledge:This survey may be considered as a pilot-study for the development of large-scale studies to understand females's demands and concerns about AI applications in breast cancer screening.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.